Epizyme (EPZM) Tops Q3 EPS by 5c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Epizyme Reports Business Progress and Third Quarter 2020 Financial Results
November 6, 2020 6:30 AM ESTCompany Reports 55% Growth in Net Revenue of TAZVERIK® Compared with 2Q 2020
Expansion of Loan Facility with Pharmakon Advisors; $150 Million Drawn Down to Fund Important Growth Initiatives and Extend Operating Runway into At Least 2023
On-Track to Initiate Efficacy Portions of Confirmatory Trials in ES and FL and Phase 2 Castration-Resistant Prostate Cancer Trial in Early 2021
Conference Call to be Held Today, November 6 at 8:00 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS... More
